PORTFOLIO NEWS Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Adds New Chief Business Officer April 25th, 2022 Read More » NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022 April 20, 2022 Read More » ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting April 12, 2022 Read More » Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting April 8, 2022 Read More » NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio April 8, 2022 Read More » Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update April 7, 2022 Read More » Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors April 5, 2022 Read More » eFFECTOR Therapeutics Announces Transition in Clinical Leadership April 4, 2022 Read More » Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy April 1, 2022 Read More » NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors March 31, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Adds New Chief Business Officer April 25th, 2022 Read More »
ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting April 12, 2022 Read More »
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting April 8, 2022 Read More »
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio April 8, 2022 Read More »
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update April 7, 2022 Read More »
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors April 5, 2022 Read More »
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy April 1, 2022 Read More »
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors March 31, 2022 Read More »
